Table 6 Protein biomarker expression in angiogenic and non-angiogenic NSCLCs according to their intracellular localization
From: Why some tumours trigger neovascularisation and others don’t: the story thus far
Expression status | Intracellular expression localization | Proteins |
|---|---|---|
Equal expression in both tumour types | Nuclear | VEGFA, TYMP, KDR, KDRp34, FIH, EPHB4, PHD1, SOD1, FGF, P53, SP1, STAT3, MEF2D, JMY, GST, CHGA |
Cytoplasm | HIF1, HIF2, VEGFA, TYMP, KDR, KDRp34, FIH, PHD1, SOD1, CXCR4, EPHB4, BCL2, EGF, EGFR, FGF, BNIP3, PI3, SP1, LON, MEF2D, GST, CHGA, SYP | |
Membrane | CA9, MEF2D | |
Higher expression in angiogenic tumours than in non-angiogenic tumours in at least one subcellular location | Nuclear | HIF1, PHD2, PHD3, CXCR4, BNIP3, PI3, EGF, FOS |
Cytoplasm | PHD2, TSP (stroma), DLL4 (endothelium), FOS, STAT3 | |
Membrane | None | |
Higher expression in non-angiogenic tumours than in angiogenic tumours in at least one subcellular location | Nuclear | EPHB2, EPHB3,TRAP1 |
Cytoplasm | CA9, PHD3, EPHB2, EPHB3, NCAM, P53, TRAP1, JMY | |
Membrane | EPHB3, GST |